HHS Nominee Azar: Great News For Industry But ACA Reform Will Be Priority

Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.

HHS Building_1200

If any more proof is needed, Trump's nomination of former Eli Lilly & Co.executive Alex Azar to become HHS secretary should confirm the Administration is not planning to take on the industry over drug pricing, despite the president's rhetoric.

Azar spent 10 years as an executive at the Big Pharma and is expected to be an even stronger industry...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access